Zoetis, Inc. Stock Plummets to New 52-Week Low of $139.34

Zoetis, Inc., a prominent player in the Pharmaceuticals & Biotechnology sector, has recently reached a new 52-week low of USD 139.34 on September 25, 2025. This decline marks a significant downturn for the company, which has experienced a 21.08% decrease in its stock price over the past year, contrasting sharply with the S&P 500's performance of 15.79% during the same period.
With a market capitalization of USD 71,581 million, Zoetis remains a large-cap entity in its industry. The company's price-to-earnings (P/E) ratio stands at 31.00, indicating how the market values its earnings relative to its stock price. Additionally, Zoetis boasts a notable dividend yield of 60.56%, reflecting its commitment to returning value to shareholders.

Despite the recent price movement, the company's return on equity is a robust 52.68%, showcasing its efficiency in generating profits from shareholders' equity. The price-to-book ratio is recorded at 14.38, further illustrating the valuation metrics at play. As Zoetis navigates these market dynamics, its financial fundamentals remain a focal point for stakeholders.